02:28 PM EST, 01/13/2025 (MT Newswires) -- Emergent BioSolutions ( EBS ) said Monday that the Biomedical Advanced Research and Development Authority executed a contract modification for the second option period, valued at about $16.7 million, for drug product process and analytical testing validation and long-term stability for Ebanga.

Ebanga is indicated for the treatment of infection caused by Zaire Ebola virus.

BARDA is part of the Administration for Strategic Preparedness and Response within the US Department of Health and Human Services.

The option is part of Emergent's existing 10-year contract with BARDA for advanced development and procurement of Ebanga, with a maximum value of $704 million, the company said.

Shares of Emergent BioSolutions ( EBS ) fell past 5% in recent trading.

Price: 9.33, Change: -0.55, Percent Change: -5.57